ArticleESMO open2026
Patterns and quality of therapeutic care for glioma: a population-based study in Belgium between 2016 and 2019.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aimed to evaluate the patterns and quality of therapeutic care and pathological diagnosis for glioma patients by calculating process indicators across Belgian hospitals. MATERIALS AND
methodsAll Belgian patients newly diagnosed with glioma between 2016 and 2019 were identified in the Belgian Cancer Registry (BCR). The National Social Security Number was used to link pathology reports and databases providing information on diagnostic and therapeutic procedures and vital status. Eighteen process indicators for therapeutic care and seven for pathological diagnosis were assessed for measurability based on administrative data availability. Measurable indicators were reviewed by a multidisciplinary expert board, and a validation study was conducted in six pilot hospitals. Associations between process indicators and outcomes were explored where possible.
resultsNine indicators for therapeutic care and five for pathological diagnosis were measurable, though five required reformulations due to shortcomings in administrative data, mainly regarding radiotherapy dose and number of fractions. Most indicators met the predefined targets, indicating the provision of qualitative care. No low-grade gliomas received chemo- or radiotherapy without prior pathological confirmation. Concomitant chemoradiotherapy was initiated in 93.1% of surgically treated and 88.9% of biopsied glioblastoma patients (target 90%). For grade 3 astrocytoma and oligodendroglioma, the use of adjuvant chemo- and radiotherapy increased over time, meeting the 90% target by 2019. However, timely initiation of chemoradiotherapy (within 6 weeks of resection) in high-grade glioma could be improved (79.8% versus target 95%). The proportion of patients receiving chemotherapy (3.5%) or radiotherapy (2.5%) in the last 14 days of life remained below the 5% target.
conclusionsThis research provides valuable feedback to Belgian hospitals and health care providers in neuro-oncology care programmes, opening opportunities for quality enhancement. On an international level, it underscores the significance of standardized quality assessment methods in neuro-oncology, which could serve as a foundation for future benchmark initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.